Abstracts tagged "cytokines"

Abstract Number: 2510 • 2018 ACR/ARHP Annual Meeting
A Phase IIa Mechanistic Study of Anti-GM-CSF (GSK3196165) with Methotrexate Treatment in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Methotrexate
Mark C. Genovese¹, Mario Berkowitz², Philip G. Conaghan³, Katherine Davy⁴, David Inman⁵, Elena Fisheleva^6,7, Anubha Gupta⁶, Robert Janiczek⁶, Mark Layton⁸, Nina Mitchell^6,7, Jatin Patel⁹, Julia E. Smith¹⁰, Russell Williamson⁵ and Paul-Peter Tak¹¹, ¹Stanford University Medical Center, Palo Alto, CA, ²Leon Medical Research, Lauderdale Lakes, FL, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Statistics, GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, ⁵GlaxoSmithKline, Stockley Park, United Kingdom, ⁶GlaxoSmithKline, Stevenage, United Kingdom, ⁷Currently at Biomarin UK Ltd, London, United Kingdom, ⁸ImmunoInflammation, ImmunoInflammation, GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, ⁹ImmunoInflammation, GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, ¹⁰Immunoinflammation TA, GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom, ¹¹GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: GSK3196165 is a high-affinity anti-GM-CSF cytokine IgG mAb currently in development for RA, with reported efficacy using IV dosing. This study evaluated the effects…
Abstract Number: 59 • 2018 ACR/ARHP Annual Meeting
Elucidating the Expression and Role of Heparan Sulfate Proteoglycan Editing Sulfatases in Human Rheumatoid Arthritis Synovium and a Rat Adjuvant-Induced Arthritis Model
Ruby J. Siegel¹, Solomon A. Agere¹, Anil K. Singh¹ and Salahuddin Ahmed^2,3, ¹Washington State University, Department of Pharmaceutical Sciences, College of Pharmacy, Spokane, WA, ²Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, ³Division of Rheumatology, University of Washington, Division of Rheumatology, School of Medicine, Seattle, WA
Background/Purpose: Syndecans are cell-surface heparan sulfate proteoglycans (HSPGs) that modulate the receptor/ligand binding of chemokines, cytokines, and growth factors in order to facilitate cellular signaling.…
Abstract Number: 1335 • 2018 ACR/ARHP Annual Meeting
Extracellular Vesicles Induce Pro-Inflammatory Cytokines in Dermatomyositis
Krisha Desai^1,2, Majid Zeidi^3,4, Ming-Lin Liu^1,2 and Victoria P. Werth^1,2, ¹Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Department of Dermatology, Corporal Michael J. Crescenz VAMC, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴Philadelphia Veterans Affairs Medical Center, Philadelphia, PA
Background/Purpose: Extracellular vesicles (EVs) are micron-scale bilayer membrane vesicles released from almost all cell types under activation or apoptosis. They have been detected in various…
Abstract Number: 2519 • 2018 ACR/ARHP Annual Meeting
Exposure-Efficacy Analysis in DMARD Inadequate Response Rheumatoid Arthritis Patients Treated with GSK3196165 Along with Methotrexate
Anubha Gupta¹, Chiara Zecchin¹, Elena Fisheleva^1,2, Mark Layton³ and Stefano Zamuner⁴, ¹GlaxoSmithKline, Stevenage, United Kingdom, ²Currently at Biomarin UK Ltd, London, United Kingdom, ³ImmunoInflammation, ImmunoInflammation, GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, ⁴Clinical Pharmacology, GlaxoSmithKline, Stevenage, United Kingdom
Background/Purpose: GSK3196165 is an anti-GM-CSF mAb being developed for RA. In a phase IIb dose-finding study (NCT02504671), RA patients with inadequate response to methotrexate were…
Abstract Number: 96 • 2018 ACR/ARHP Annual Meeting
The Liver X Receptor Modulates Inflammatory Cytokines Based on Lxrα Polymorphism in Monocyte-Derived Macrophages and Patients with Systemic Lupus Erythematosus
Chang-Hee Suh¹, Wook-Young Baek², Hyoun-Ah Kim³ and Ju-Yang Jung², ¹Rheumatology, Ajou University School of Medicine, Suwon, Korea, Republic of (South), ²Ajou University School of Medicine, Suwon, Korea, Republic of (South), ³Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea, Republic of (South)
Background/Purpose: Liver X receptors (LXRs) have emerged as important regulators of inflammatory gene expression. Previously, we had reported that an LXRα gene promoter polymorphism (-1830…
Abstract Number: 1476 • 2018 ACR/ARHP Annual Meeting
Implication of CXCL5 (Epithelial neutrophil-activating peptide 78) in the Development of Insulin Resistance in Patients with Rheumatoid Arthritis
Sonia Peña¹, Beatriz-Segura Tejera², Raquel Lopez-Mejías³, De Vera-González AM⁴, Alejandra Gonzalez-Delgado⁵, Miguel Angel González-Gay⁶ and Iván Ferraz-Amaro⁷, ¹Rheumatology, Servicio de Reumatología, Hospital Universitario de Canarias,Spain, La Laguna, Spain, ²Rheumatology Division, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ³Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ⁴Division of Central Laboratory. Hospital Universitario de Canarias, San Cristobal de La Laguna, Spain, ⁵Division of Central Laboratory. Hospital Universitario de Canarias., Tenerife, Spain, ⁶Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL and School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain, ⁷Division of Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain, Tenerife, Spain
Background/Purpose: The chemokine molecule CXCL5 (C-X-C motif chemokine ligand 5, also known as epithelial neutrophil activating peptide 78 -ENA78-) constitutes a link between obesity, inflammation…
Abstract Number: 2763 • 2018 ACR/ARHP Annual Meeting
Utility of Serum Free Light Chains, Antiphospholipid Antibodies, and Cytokines in Giant Cell Arteritis
Matthew J. Koster¹, Melissa Snyder², Michel Villatoro-Villar¹, Cynthia S. Crowson³, Tanaz A. Kermani⁴ and Kenneth J. Warrington⁵, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, ³Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Medicine, Division of Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁵Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: To investigate the utility of serum free light chains (FLC), antiphospholipid antibodies (APL), and cytokines in the evaluation of patients with biopsy-proven giant cell…
Abstract Number: 105 • 2018 ACR/ARHP Annual Meeting
Immunologic Properties of Cutaneous Lupus Erythematosus (CLE) Patients Refractory to Antimalarials Compared to Patients That Respond to Antimalarials
Majid Zeidi^1,2, Krisha Desai^3,4, Hee Joo Kim^3,4,5 and Victoria P. Werth^3,4, ¹University of Pennsylvania, Philadelphia, PA, ²Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, ³Department of Dermatology, Corporal Michael J. Crescenz VAMC, Philadelphia, PA, ⁴Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵Department of Dermatology, Gachon Gil Medical Center, School of Medicine, Gachon University, Incheon, Korea, Republic of (South)
Background/Purpose: Two major therapies for cutaneous lupus erythematosus (CLE) are the antimalarials, hydroxychloroquine (HCQ) and quinacrine (QC). HCQ is often the first-line therapy for CLE,…
Abstract Number: 1487 • 2018 ACR/ARHP Annual Meeting
Correlation between Cytokine Levels and Power-Doppler Ultrasound Activity Is BMI Dependent, and Different in ACPA Positive and ACPA Negative RA with Wrist Arthritis
Ottar Gadeholt¹, Erin Arnold², Corinne Gorman³, Tobias Mueller⁴ and William Arnold², ¹Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Wuerzburg, Germany, ²Orthopedics and Rheumatology of the North Shore, Skokie, IL, ³Orthopaedics & Rheumatology of the North Shore, Skokie, IL, ⁴Department of Bioinformatics, University of Wuerzburg, Wuerzburg, Germany
Background/Purpose: Multiple cytokines are assumed to be involved in RA pathogenesis. It has been hypothesized that ACPA-negative RA with wrist affection constitutes a separate entity.…
Abstract Number: 2837 • 2018 ACR/ARHP Annual Meeting
Diminished STAT-3 Phosphorylation and Associated Cell Pathways Characterize MMF-Treated Systemic Lupus Erythematosus Patients
Samantha Slight-Webb¹, Joel M. Guthridge¹, Eliza Chakravarty¹, Hua Chen¹, Rufei Lu², Krista M. Bean¹, Holden T. Maecker³, Paul J. Utz⁴ and Judith A. James⁵, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Stanford University, Stanford, CA, ⁴Medicine, Stanford University School of Medicine, Stanford, CA, ⁵Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Mycophenolate mofetil (MMF) is a commonly used medication to treat major organ involvement in SLE, specifically in patients with lupus nephritis. The safety and…
Abstract Number: 137 • 2018 ACR/ARHP Annual Meeting
Autoantibody-Inducing CD4 T (aiCD4 T) Cells Which Induce Systemic Lupus Erythematosus (SLE) Contain Follicular Helper T Cell in Addition to the Major IL-21-Producing CXCR5-ICOShiPD1hi Population: Self-Organized Criticality Theory As the Cause of SLE
Ken Tsumiyama and Shunichi Shiozawa, Institute for Rheumatic Diseases, Nagahama, Japan
Background/Purpose: We have shown that repeated immunization with antigen induces systemic lupus erythematosus (SLE) in the mice otherwise not prone to spontaneous autoimmune diseases. We…
Abstract Number: 1732 • 2018 ACR/ARHP Annual Meeting
Alterations of Body Composition in Patients with Systemic Scleroderma Are Associated with Disease Activity, Physical Activity and Serum Levels of Inflammatory Cytokines
Sabina Oreska^1,2, Maja Spiritovic^1,3, Petr Cesak⁴, Michal Cesak⁵, Hana Storkanova^1,2, Hana Smucrova¹, Barbora Hermankova^1,3, Barbora Sumova^1,2, Olga Ruzickova^1,6, Herman F Mann^1,7, Karel Pavelka^1,2, Ladislav Šenolt^1,2, Jiri Vencovsky^1,8, Radim Becvar^1,2 and Michal Tomcik^1,2, ¹Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ²Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Department of Physiotherapy, Faculty of Physical Education and Sports, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Body Composition Laboratory, Faculty of Physical Education and Sports, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁵Faculty of Physical Education and Sports, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁶Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁷First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁸Department Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Fibrosis of the skin and visceral organs, especially digestive tract, and musculoskeletal involvement in systemic sclerosis (SSc) can have a negative impact on body…
Abstract Number: 2902 • 2018 ACR/ARHP Annual Meeting
Antibodies to PAD4 Drive Monocyte Activation and Differentiation into Osteoclast-like Cells
Pooja Naik¹, Jing Shi², Felipe Andrade³ and Erika Darrah⁴, ¹Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Department of Medicine/Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Agonistic antibodies to Peptidylarginine Deiminase 4 (PAD4) are hallmarks of a severe form of rheumatoid arthritis (RA) characterized by the most erosive joint damage…
Abstract Number: 155 • 2018 ACR/ARHP Annual Meeting
Polyfunctional Synovial T-Cell Responses and Synovial Invasiveness Repressed By Blockade of Phosphodiesterase 4
Sarah M. Wade¹, Mary Canavan¹, Trudy McGarry¹, Siobhan C. Wade¹, Ronan Mullan², Douglas J. Veale³ and Ursula Fearon¹, ¹Molecular Rheumatology, School of Medicine, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland, ²Department of Rheumatology,, Tallaght Hospital, Dublin, Ireland, ³Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin, Ireland
Background/Purpose: Genetic and functional studies strongly support the role of T-cells in PsA pathophysiology. Effective targeting of T-cells requires a detailed understanding of their phenotypic…
Abstract Number: 1743 • 2018 ACR/ARHP Annual Meeting
Serum Markers Potentially Associated with PAH in Systemic Sclerosis; A Targeted Screening Approach
Anders Heiervang Tennøe¹, Håvard Fretheim², Oyvind Midtvedt², Torhild Garen², Thor Ueland³, Pål Aukrust², Arne K Andreassen², Einar Gude², Øyvind Molberg² and Anna-Maria Hoffmann-Vold², ¹Rheumatology, Oslo University Hospital, Oslo, Norway, ²Oslo University Hospital, Oslo, Norway, ³Research Institute of Internal Medicine Research, Oslo University Hospital, Oslo, Norway
Background/Purpose: Pulmonary arterial hypertension (PAH) is a feared complication in systemic sclerosis (SSc). Detection of PAH at a preclinical stage is important as early diagnosis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.